Clinical Trial Update: Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports results for combining cabozantinib (Cabometyx) with avelumab in patients with metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Cabometyx (cabozantinib)

Snippet

Sponsor: University of Utah | Conditions: Renal Cell Carcinoma | Phase 1 | Status: COMPLETED